Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
245 articles with Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. And Boehringer Ingelheim Corporation Initiate Rheumatoid Arthritis Collaboration; Deal Potentially Worth Over $75 Million